作者: William D. Figg , Maha H. Hussain , James L. Gulley , Philip M. Arlen , Jeanny B. Aragon-Ching
DOI: 10.1016/J.JURO.2008.11.026
关键词:
摘要: Purpose: We determined whether thalidomide can prolong progression-free survival in men with biochemically recurrent prostate cancer treated limited androgen deprivation therapy.Materials and Methods: A total of 159 patients were enrolled a double-blind randomized trial to determine if improve the efficacy gonadotropin-releasing hormone agonist responsive an increasing specific antigen after primary definitive therapy for cancer. Patients 6 months followed by 200 mg per day oral or placebo (oral phase A). At time progression was restarted additional months. then crossed over opposite drug until B). Testosterone dihydroxytestosterone likewise monitored throughout study.Results: During ora...